Denali Therapeutics (DNLI) Other financing activities (2017 - 2026)

Denali Therapeutics (DNLI) has reported Other financing activities for 10 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 1025.21% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $14.6 million (down 14.17% YoY), while the FY2025 annual figure was $8.5 million, down 51.35% from the prior year.
• Other financing activities rose to $6.7 million in Q1 2026 per DNLI's latest filing, from $3.2 million in the prior quarter.
• Across five years, Other financing activities topped out at $9.0 million in Q2 2023 and bottomed at -$13.1 million in Q4 2023.
• Historically, Other financing activities has averaged $2.8 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2023 — Other financing activities slumped 481.69% — and 2026, when it jumped 1025.21%.
• Denali Therapeutics' Other financing activities stood at $3.4 million in 2022, then plunged by 481.69% to -$13.1 million in 2023, then soared by 131.68% to $4.2 million in 2024, then slipped by 22.41% to $3.2 million in 2025, then surged by 107.66% to $6.7 million in 2026.
• Business Quant data shows DNLI's Other financing activities at $6.7 million in Q1 2026, $3.2 million in Q4 2025, and $583000.0 in Q3 2025.